Background Rezafungin, a novel echinocandin with once-weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While c.....

Background The efficacy and safety of rezafungin in invasive candidiasis (IC) and candidaemia was demonstrated in the Phase 2 STRIVE and Phase 3 ReSTORE trials, and an additional cohort of patients ...

Rezafungin, der neueste Echinocandinvertreter. Gezielt eingesetzt, klug entschieden, bessere Ergebnisse. Candida auris. Pneumocystis jirovecciii. Aspergillus & Candida.

YouTube video by IDIM IDIM

New data found that one dose of rezafungin demonstrated good safety and efficacy compared with caspofungin to treat patients with candidemia or invasive candidiasis.

Achieving and maintaining therapeutic drug exposures with antifungals can be challenging in special patient populations, such as those with organ dysf…

Candidemia and invasive candidiasis (IC) remain challenging infections with morbidity and mortality estimated around 40% (1). These infections are commonly associated with healthcare exposure, especia...

Thieme E-Books & E-Journals

Invasive candidiasis is a common healthcare-associated infection with significant morbidity and mortality. Candida auris in particular has emerged as …

Rezafungin is a second-generation echinocandin that has shown activity against a range of Candida species including wild-type and azole- and echinocandin-resistant isolates (1–3). Rezafungin has improved chemical and biological properties that are distinct from other echinocandins. Most notably, the modified backbone of rezafungin leads to a stable chemical structure with reduced metabolism and degradation relative to other echinocandins. This results in a longer half-life, which allows for weekly dosing, improved tissue penetration, and reduced organ toxicity (4, 5). Less frequent dosing also results in high front-loaded exposure, which, along with good distribution to and penetration at infection sites may allow earlier mycological clearance from sites of infection with the potential to prevent the emergence of resistance (4, 6–10). Rezafungin was approved in 2023 by the United States Food and Drug Administration for the treatment of candidemia and invasive candidiasis based on clinical efficacy and safety data from the randomized Phase 2 STRIVE and Phase 3 ReSTORE clinical trials (10–12).

Podcast Episode · ID:IOTS - Infectious Disease Insight Of Two Specialists · 23 February · 38m

In the second interview segment with George Thompson, MD, he provides feedback on patient profiles and prescribing practices for the antifungal.

AbstractBackground. Chronic pulmonary aspergillosis (CPA) is a serious lung disorder caused by Aspergillus fungal infection with high morbidity and mortali

Rezafungin (Rezzayo®) is a next-generation echinocandin antifungal with improved pharmacokinetic properties over first-generation echinocandins that allows for once-weekly rather than once-daily intra...

Background Rezafungin, a novel echinocandin with once-weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While c.....

Candidemia and invasive candidiasis (IC) remain challenging infections with morbidity and mortality estimated around 40% (1). These infections are commonly associated with healthcare exposure, especia...

AbstractBackground. Rezafungin is approved for use in adults with candidemia and/or invasive candidiasis based on data from the ReSTORE trial (NCT03667690)